Among the causes of death due to cancer, brain tumors are ranked second in the pediatric age group and fourth in middle-aged man and malignant gliomas are uniformly fatal with only 50 percent of patients surviving one year from initial diagnosis. These stark statistics underscore the urgent need for improved therapies along with capabilities that would provide for early therapeutic assessment of efficacy in these patients. A sensitive and early predictor of therapeutic outcome for patients would provide for improved care and the opportunity to individualize and adjust the treatment to each patient. The central hypothesis of this project is that the effectiveness of therapeutic interventions can be determined prior to tumor shrinkage using quantitative MR diffusion, perfusion and 1H spectroscopic methods. Both animal and human brain tumors will be evaluated using MR following therapeutic intervention including chemotherapy, radiation, gene, nanoparticles and antiangiogenic therapies. This research program will provide new mechanistic insights into: The use of MRI/S for the early detection of brain tumor response to therapy and the effects of neovascularization on therapy (Project 1); The sensitivity and resolution of MRI/S for the detection of therapeutic transgene delivery, function and therapeutic efficacy in brain tumors (Project 2); The capability of using NanoPlatforms for the delivery of image contrast agents and potentially therapeutic drugs to brain tumors (Project 3); and The predictiveness of MRI for the early assessment of human brain tumor response to therapy (Project 4). This research plan is an outgrowth of the progress made with previous NCI support. Four interactive projects and four cores are proposed. The Administrative Core A provides administrative support along with internal and external review for all projects. The Animal MR Imaging Core B provides the necessary MRI/S services for Projects 1-3. The Digital Image Processing Core C provides a centralized and high-throughput capability for the digital post processing of all acquired MR data for all projects (Projects 1-4). The Biostatistical Core D provides statistical support to all projects.
| Smith, Andrew; Pawar, Mercy; Van Dort, Marcian E et al. (2018) Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors. J Ocul Pharmacol Ther 34:477-485 |
| Akgül, Seçkin; Li, Yinghua; Zheng, Siyuan et al. (2018) Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep 24:463-478.e5 |
| Pal, Anupama; Rehemtulla, Alnawaz (2018) Imaging Proteolytic Activities in Mouse Models of Cancer. Methods Mol Biol 1731:247-260 |
| Durmo, Faris; Lätt, Jimmy; Rydelius, Anna et al. (2018) Brain Tumor Characterization Using Multibiometric Evaluation of MRI. Tomography 4:14-25 |
| Van Dort, Marcian E; Galbán, Stefanie; Nino, Charles A et al. (2017) Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). ACS Med Chem Lett 8:808-813 |
| Galbán, Stefanie; Al-Holou, Wajd N; Wang, Hanxiao et al. (2017) MRI-Guided Stereotactic Biopsy of Murine GBM for Spatiotemporal Molecular Genomic Assessment. Tomography 3:9-15 |
| Barthel, Floris P; Wei, Wei; Tang, Ming et al. (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49:349-357 |
| Hu, Xin; Martinez-Ledesma, Emmanuel; Zheng, Siyuan et al. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19:786-795 |
| Nyati, Shyam; Young, Grant; Ross, Brian Dale et al. (2017) Quantitative and Dynamic Imaging of ATM Kinase Activity. Methods Mol Biol 1596:131-145 |
| Galbán, Stefanie; Apfelbaum, April A; Espinoza, Carlos et al. (2017) A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther 16:2340-2350 |
Showing the most recent 10 out of 170 publications
